BIO CEO & Investor Conference 2006 to Webcast OrthoLogic Presentation
08 Febbraio 2006 - 4:08PM
PR Newswire (US)
TEMPE, Ariz., Feb. 8 /PRNewswire-FirstCall/ -- OrthoLogic Corp.
(NASDAQ:OLGC) announced today that management will provide an
overview of the Company and its lead compound for tissue and bone
healing, Chrysalin(R) (TP508), at the BIO CEO Investor Conference
2006. The presentation will be delivered at 11:30 a.m. EST on
Wednesday, February 15, 2006 at The Waldorf=Astoria Hotel in New
York. The presentation will be webcast live and may be accessed by
visiting the Investors section of the Company's website,
http://www.orthologic.com/. It will be archived for 60 days.
OrthoLogic is a biotechnology company focused on the development
and commercialization of the novel synthetic peptide Chrysalin(R)
(TP508) in two lead indications, both of which represent areas of
significant unmet medical need -- fracture repair and diabetic foot
ulcer healing. Based on the Company's pioneering scientific
research of the natural healing cascade, OrthoLogic has become the
leading company focused on tissue and bone repair. OrthoLogic is
committed to developing a pipeline of novel peptides and other
molecules aimed at helping patients with equally under-served
conditions. The Company maintains exclusive worldwide rights for
Chrysalin. OrthoLogic's corporate headquarters are in Tempe,
Arizona. For more information, please visit the Company's website:
http://www.orthologic.com/. DATASOURCE: OrthoLogic Corp. CONTACT:
Media, Lauren Tortorete of Biosector 2, +1-212-845-5609; or
Investors, Melanie Friedman of Stern Investor Relations,
+1-212-362-1200, both for OrthoLogic Corp. Web site:
http://www.orthologic.com/
Copyright
Grafico Azioni Orthologic (MM) (NASDAQ:OLGC)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Orthologic (MM) (NASDAQ:OLGC)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Orthologic (MM) (NASDAQ): 0 articoli recenti
Più Orthologic (MM) Articoli Notizie